Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

2014 ◽  
Vol 17 (2) ◽  
pp. 160-166 ◽  
Author(s):  
J. Salvador ◽  
L. Manso ◽  
J. de la Haba ◽  
A. Jaen ◽  
E. Ciruelos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy

scholarly journals First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: A phase II study

BMC Cancer ◽  
2005 ◽  
Vol 5 (1) ◽  
Author(s):  
Djelila Allouache ◽  
Sulochana R Gawande ◽  
Michele Tubiana-Hulin ◽  
Nicole Tubiana-Mathieu ◽  
Sophie Piperno-Neumann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
Locally Recurrent

scholarly journals Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer

2006 ◽  
Vol 94 (11) ◽  
pp. 1604-1609 ◽  
Author(s):  
F Ciardiello ◽  
T Troiani ◽  
F Caputo ◽  
M De Laurentiis ◽  
G Tortora ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document